Tornier, LifeCell in pig-tissue matrix pact
This article was originally published in Clinica
Extremity orthopaedics specialist Tornier has teamed up with regenerative human tissue company LifeCell, to distribute the latter's new-generation reconstructive tissue matrix. The exclusive deal, of which no financial details were disclosed, will see the two firms work together to develop the product for orthopaedic soft tissue repair applications such as tendon repair. Tornier will then distribute the product to orthopaedic and podiatric surgeons under the brand name Conexa. The product is already approved by the FDA for these applications. The new tissue matrix uses porcine-derived tissue technology which, according to Edina, Minnesota-based Tornier, is equally as effective at promoting tissue regeneration as the company's flagship human tissue matrix, AlloDerm.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.